Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$881.69M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$890.90M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$872.01M
EBITDA Margin
-5250.17%
TTM Avg
-5250.17%
3Y Avg
-5250.17%
5Y Avg
-5250.17%
Market Cap
$869.18M
EBITDA Margin
-170.39%
TTM Avg
-102.27%
3Y Avg
-63.10%
5Y Avg
-63.10%
Market Cap
$854.88M
EBITDA Margin
43.46%
TTM Avg
29.10%
3Y Avg
-0.91%
5Y Avg
-6.21%
Market Cap
$853.28M
EBITDA Margin
-9.76%
TTM Avg
-14.11%
3Y Avg
-27.72%
5Y Avg
-36.15%
Market Cap
$912.07M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$852.84M
EBITDA Margin
-17.48%
TTM Avg
-35.83%
3Y Avg
-4.31%
5Y Avg
17.66%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $881.69M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $886.14M | 18.58% | 12.56% | -0.37% | 4.16% |
| Arbutus Biopharma Corp (ABUS)vs › | $890.90M | -189.51% | -701.94% | -497.69% | -575.23% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $872.01M | -5250.17% | -5250.17% | -5250.17% | -5250.17% |
| SL Science Holding Ltd (SLBT)vs › | $869.18M | -170.39% | -102.27% | -63.10% | -63.10% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $854.88M | 43.46% | 29.10% | -0.91% | -6.21% |
| SI-BONE, Inc. (SIBN)vs › | $853.28M | -9.76% | -14.11% | -27.72% | -36.15% |
| HealthStream, Inc. (HSTM)vs › | $912.07M | 20.95% | 21.20% | 20.44% | 19.67% |
| QuidelOrtho Corporation (QDEL)vs › | $852.84M | -17.48% | -35.83% | -4.31% | 17.66% |
| CeriBell, Inc. (CBLL)vs › | $921.51M | -64.07% | -61.50% | -81.15% | -81.15% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
